Pfizer Pays 330 Million Upfront For Starna CAR-T Programs
The deal covers three pre-IND autoimmune programs and the delivery platform behind them, and none of it has touched a patient yet.
The factory moves inside the patient.
Pfizer agreed on November 18 to pay Starna Therapeutics $330 million upfront for three in vivo CAR-T programs aimed at autoimmune diseases.
The full shape is bigger than the headline payment. Starna can earn up to $2.3 billion more in development and commercial milestones, plus royalties on net sales, which takes the deal's ceiling to about $2.63 billion. Pfizer takes exclusive rights outside Greater China to develop, manufacture and sell all three programs, and it also licensed Starna's in vivo CAR-T technology for use across inflammation and immunology, and in oncology.
The options widen it further. Pfizer holds options to license compounds from a separate research collaboration on exclusive terms, and an option to extend its territory into Greater China later. It leads clinical development everywhere outside Greater China, and it plans to manufacture the finished drug product for the first clinical trials at its own facilities in the United States.
The science is the reason for the price. Today's CAR-T therapies are built outside the body: doctors collect a patient's T cells, engineer them in a lab and infuse them back, a process that takes weeks and a specialized center. Starna's approach delivers an RNA payload by targeted lipid nanoparticles, and the reprogramming happens inside the patient instead. Starna is based in Suzhou, China, and its platform steers those particles to targets beyond the liver.
The evidence boundary is exact. All three programs are pre-IND, which means they haven't entered human testing and haven't filed the paperwork to start. No patient has received any of them, and no safety or efficacy data in people exists. The $330 million buys position in a race, not a product, and the milestone structure means most of the $2.63 billion only moves if the science survives contact with patients.
Autoimmune disease is where the field's second act is forming. CAR-T began in blood cancers, and a deep reset of the immune system could hold diseases that today's drugs only manage. Michael Vincent, Pfizer's chief inflammation and immunology officer, said the patients who might benefit most are those for whom today's options fall short. That sentence is the market the deal is priced on, and the first trial filings will show whether Pfizer moves as fast as the upfront payment suggests.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.